AKT1 and hepatocellular carcinoma: These agents include potent PI3K inhibitors (LY294002, DZW-310,243 740Y-P,244 copanlisib245) and AKT inhibitors (MK2206, AKT inhibitor VIII).246,247 These agents elicited consistent anti-tumor effectiveness such as proliferation inhibition and apoptosis induction in HCC cells.230,248,249 Other unselective agents have also found to inhibit HCC.230,250 For example, celecoxib, a non-steroidal anti-inflammatory drug, targets the cyclooxygenase 2 (COX-2)/AKT pathway and was sufficient to inhibit the progress of HCC by inhibiting lipogenesis.250